Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Merck

- PMLiVE

US FDA accepts supplemental Biologics License Application for Merck’s Enflonsia

The treatment is to protect children under two years of age from respiratory syncytial virus

- PMLiVE

AstraZeneca’s Baxfendy approved by US FDA for adults with uncontrolled hypertension

Hypertension affects more than 1.4 billion people worldwide and many patients remain uncontrolled despite multiple therapies

- PMLiVE

US FDA approves Taiho’s Inqovi for older adults with acute myeloid leukaemia

In 2026, an estimated 22,720 people in the US will be diagnosed with AML

- PMLiVE

Lilly’s Foundayo approved by US FDA as oral GLP-1 for weight loss

Taken at any time of the day, the oral GLP-1 is the only pill to have no food or water restrictions

- PMLiVE

Merck agrees on $2.2bn deal with Quotient Therapeutics to develop IBD treatment

Quotient’s somatic genomics platform technology will be used to develop the treatment

- PMLiVE

J&J’s nipocalimab gets FDA Fast Track designation for lupus

The autoimmune disease affects approximately three to five million people globally

- PMLiVE

Moderna and Merck announce data from melanoma combination therapy study

Skin cancer is one of the most common cancers in the US, with melanoma accounting for the majority of skin cancer deaths

- PMLiVE

Merck announces agreement with US government to reduce prices of prescription medication

The pharma company will invest more than $70bn in the US to boost production and innovation

- PMLiVE

Merck agrees deal with Cidara Therapeutics worth almost $9.2bn

Cidara’s long-acting viral flu drug showed significant protection in phase 2 results

- PMLiVE

Merck ends development agreement with Dr Falk Pharma for monoclonal antibody

Merck will take full control of developing MK-8690, an investigational monoclonal antibody candidate

- PMLiVE

Merck and Blackstone agree on funding for cancer protein antibody

The funding will support late-stage clinical development of the investigational antibody-drug conjugate

- PMLiVE

David Weinreich appointed as Merck’s head of R&D and CMO for healthcare

Weinreich brings clinical development and venture capital experience to the role

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links